Medications for Gestational Hypertension
For non-severe gestational hypertension, extended-release nifedipine or labetalol are the first-line oral agents, with nifedipine often preferred due to once-daily dosing that improves adherence; for severe hypertension requiring urgent treatment, use IV labetalol, immediate-release oral nifedipine, or IV hydralazine, with treatment initiated within 30-60 minutes to reduce stroke risk. 1, 2
First-Line Oral Agents for Non-Severe Hypertension
The most recent 2025 Circulation guideline establishes clear first-line options 1:
Extended-release nifedipine: Often selected initially due to once-daily administration, which improves patient adherence. Side effects include headaches, tachycardia, and edema.
Labetalol: Reasonable alternative or can be combined with nifedipine for uncontrolled BP. Requires TID or QID dosing due to accelerated drug metabolism during pregnancy. Contraindicated in reactive airway disease. Minimal risks include potential fetal growth restriction, fetal bradycardia, and hypoglycemia, but no teratogenicity reported.
Methyldopa: Third option with longest-term infant outcome data available, but poorly tolerated due to side effects (peripheral edema, dry mouth, lightheadedness, drowsiness, mood effects). More commonly used in low- and middle-income countries where it may be the only available agent 1.
Important caveat: Meta-analysis data show β-blockers and calcium channel blockers are more effective than methyldopa for preventing severe hypertension 1. There is no compelling evidence supporting one agent over another between nifedipine and labetalol 1.
Medications for Severe Hypertension
When BP reaches ≥160/110 mmHg, this constitutes a hypertensive emergency requiring urgent treatment 3, 2:
First-line options (treatment should occur within 30-60 minutes) 2:
- IV labetalol
- Immediate-release oral nifedipine (particularly useful when IV access unavailable)
- IV hydralazine
Evidence strongly favors nifedipine: Network meta-analysis demonstrates nifedipine is superior to hydralazine for successful treatment of severe hypertension (OR 4.13) without increased risk of cesarean delivery or maternal side effects 4. A 2022 systematic review confirmed nifedipine has the lowest risk of persistent hypertension compared to both hydralazine (RR 0.40) and labetalol (RR 0.71) 5.
Avoid sublingual nifedipine - use immediate-release oral formulation instead 3.
Contraindicated Medications
Absolutely contraindicated 1:
- ACE inhibitors
- Angiotensin II receptor blockers
- Mineralocorticoid receptor antagonists
- Direct renin inhibitors
These agents cause fetal teratogenicity and oligohydramnios.
- Diuretics (except for pre-existing chronic hypertension)
- Atenolol (safety concerns in early/late pregnancy, though evidence is mixed)
Second-Line Options
If first-line agents fail or are contraindicated due to allergies or intolerances, second-line therapies can be added 1. For the rare circumstance where successive appropriate doses of first-line agents fail to control acute severe hypertension, emergent consultation with anesthesiology, maternal-fetal medicine, or critical care is recommended 2.
Common Pitfalls
- Using short-acting nifedipine for maintenance: Reserve short-acting formulation only for rapid treatment of severe hypertension; use extended-release for maintenance 1
- Inadequate labetalol dosing frequency: Must adjust to TID or QID due to accelerated metabolism in pregnancy 1
- Delayed treatment of severe hypertension: Treatment must begin within 30-60 minutes to reduce maternal stroke risk 2
- Prescribing atenolol: Multiple guidelines recommend against this specific β-blocker in pregnancy 3, 6